CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

DISEASE CHARACTERISTICS:

Histologically confirmed ovarian epithelial, primary peritoneal serous, or fallopian tube cancer

Recurrent or persistent disease

Elevated CA 125, defined as ≥ 40 U/mL on 2 separate consecutive measurements taken ≥ 1 week apart
No definitive disease OR small-volume disease (≤ 2 cm by spiral or conventional CT scan or clinical exam)
Asymptomatic disease

PATIENT CHARACTERISTICS:

Age

26 and over (age 18 to 25 allowed provided there is closure of the epiphyses on radiography)

Performance status

ECOG 0-1

Life expectancy

More than 6 months

Hematopoietic

Absolute neutrophil count ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3
No bleeding disorders
No hemorrhage ≥ grade 2 within the past 12 months

Hepatic

Bilirubin ≤ 1.5 times upper limit of normal (ULN)
Alkaline phosphatase ≤ 2.5 times ULN
ALT and/or AST ≤ 2.5 times ULN
Albumin ≥ 3.2 g/dL
PT/PTT ≤ 1.5 times ULN
INR ≤ 1.5

Renal

Creatinine ≤ 1.5 times ULN OR
Creatinine clearance ≥ 60 mL/min

Cardiovascular

QTc ≤ 460 msec by ECG
No unstable angina within the past 6 months
No decompensated congestive heart failure within the past 6 months
No myocardial infarction within the past 6 months
No serious cardiac arrhythmias or conduction abnormalities, including any history of recurrent ventricular arrhythmia, within the past 6 months
No cardiomyopathy
No history of syncope associated with arrhythmia
No uncontrolled hypertension within the past 3 weeks, defined as systolic blood pressure > 150 mm Hg or diastolic blood pressure > 90 mm Hg on ≥ 2 of 3 blood pressure readings taken ≥ 5 minutes apart
No thrombotic cardiovascular events, including transient ischemic attacks, within the past 12 months

Gastrointestinal

Able to take oral medication
No malabsorption syndromes
No active gastrointestinal bleeding (hematemesis, hematochezia, or melena), unrelated to cancer, within the past 3 months
No requirement for IV alimentation

Other

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 3 months after study participation
No active infection
No uncontrolled diabetes
No dementia, altered mental status, or uncontrolled psychiatric illness that would preclude giving informed consent or study compliance
No other serious uncontrolled medical disorder that would preclude study participation
No other active malignancy within the past 3 years except treated limited stage basal cell or squamous cell skin cancer or carcinoma in situ of the breast or cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy

No prior exposure to mouse antibodies
No prior vascular endothelial growth factor (VEGF) or VEGF-receptor targeted therapy
No other prior antiangiogenic anticancer therapy, including thalidomide
No concurrent prophylactic colony-stimulating factors (i.e., filgrastim [G-CSF] or sargramostim [GM-CSF])
No concurrent immunotherapy

Chemotherapy

Prior chemotherapy allowed provided patient received only a first-line platinum-based chemotherapy regimen with or without systemic consolidation chemotherapy
At least 3 weeks since prior chemotherapy and recovered (excluding alopecia)
No concurrent chemotherapy

Endocrine therapy

At least 3 weeks since prior hormonal therapy for ovarian cancer and recovered
Concurrent hormone replacement therapy allowed
No concurrent chronic oral or IV corticosteroids
No concurrent hormonal therapy, including tamoxifen

Radiotherapy

No concurrent radiotherapy

Surgery

More than 4 weeks since prior major surgical procedure
No prior gastric resection

Other

More than 3 weeks since prior investigational therapy
More than 4 weeks since prior major medical interference with the peritoneum or pleura
More than 3 months since prior treatment for active ulcer disease
No prior consolidation intraperitoneal therapy using cytotoxic agents for ovarian cancer

No concurrent antiarrhythmics

Beta blockers or calcium channel blockers used for other indications allowed
No concurrent grapefruit juice

No concurrent therapeutic anticoagulant therapy or chronic daily aspirin > 325 mg/day

Concurrent low-dose anticoagulants for maintenance of central venous access allowed
No other concurrent experimental or anticancer therapy for the primary disease